Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31733
Title: | Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study) | Authors: | Kreuter, Michael Vansteenkiste, Johan Fischer, Jürgen Eberhardt, Wilfried Zabeck, Heike Kollmeier, Jens Serke, Monika Frickhofen, Norbert Reck, Martin Engel-Riedel, Walburga Neumann, Silke THOMEER, Michiel Schumann, Christian De Leyn, Paul Graeter, Thomas Stamatis, Georgios Griesinger, Frank Thomas, Michael |
Issue Date: | 2016 | Publisher: | ELSEVIER SCIENCE INC | Source: | Journal of thoracic oncology, 11 (1) , p. 85 -93 | Abstract: | Introduction: Adjuvant chemotherapy in non-small cell lung cancer (NSCLC) improves survival but is associated with significant toxicity. The Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (TREAT study) was designed to test the hypothesis that a protocol with reduced toxicity might improve feasibility of postoperative delivery of adjuvant chemotherapy drugs to patients with NSCLC, thereby improving compliance and, potentially, survival. Introduction: Adjuvant chemotherapy in non-small cell lung cancer (NSCLC) improves survival but is associated with significant toxicity. The Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (TREAT study) was designed to test the hypothesis that a protocol with reduced toxicity might improve feasibility of postoperative delivery of adjuvant chemotherapy drugs to patients with NSCLC, thereby improving compliance and, potentially, survival.Methods: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). The primary end-point analysis showing that CPx is safe and feasible with dose delivery superior to that of CVb has already been published. Here we report the 3-year follow-up results of the secondary efficacy end points-overall, relapse-free, distant metastasis-free, and local relapse-free survival also with regard to histologic diagnosis.Results: After a median of 39 months, no significant differences in any of the outcome parameters between CVb and CPx were observed. Also, histologic diagnosis and tumor size in stage IB did not influence survival in the CPx-treated patients. Yet, Cox regression analyses showed that overall survival at 3 years was significantly correlated with feasibility and the occurrence of dose-limiting toxicity.Conclusions: Although adjuvant chemotherapy with CPx is safe and characterized by less toxicity and better dose delivery than CVb, overall survival was not influenced by treatment arm in the context of this phase II trial. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
Keywords: | Non-small cell lung cancer;Adjuvant chemotherapy;Pemetrexed;Outcome;Toxicity | Document URI: | http://hdl.handle.net/1942/31733 | ISSN: | 1556-0864 | e-ISSN: | 1556-1380 | DOI: | 10.1016/j.jtho.2015.09.014 | ISI #: | WOS:000373094200010 | Rights: | 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1556086415000234-mainTreatFU.pdf Restricted Access | Published version | 711.56 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
8
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
26
checked on Sep 12, 2024
Page view(s)
18
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.